Akèy › Anemi Refraktè ak Eksè Blast
Etid klinik pou Anemi Refraktè ak Eksè Blast ap rekrite nan Etazini
19 etid pou Anemi Refraktè ak Eksè Blast ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX6 etid
- Seattle, WA5 etid
- Washington, DC3 etid
- New York City, NY3 etid
- Boston, MA3 etid
- Columbus, OH3 etid
Pa eta
- Maryland3 etid
- Massachusetts3 etid
- New York3 etid
- North Carolina3 etid
- Ohio4 etid
- Texas7 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Ap rekriteFaz 1/2
Laj 12 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06303193Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Ap rekriteFaz 2
Laj 6 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT01861106Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Ap rekriteFaz 2
Laj 4 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT01174108Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT00801489Luspatercept + Darbepoetin in MDS
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07096297Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07249346Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Jun 25, 2026 · NCT03314974211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Ap rekrite
Laj 0 a 25 · Tout sèks · Mizajou May 13, 2026 · NCT05794880A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Ap rekriteFaz 1/2
1 Month – 25 Years · Tout sèks · Mizajou Apr 15, 2026 · NCT06839456MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Apr 6, 2026 · NCT05735717A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Ap rekriteFaz 2
Jiska laj 21 · Tout sèks · Mizajou Mar 13, 2026 · NCT04644016Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT06680752HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Ap rekriteFaz 2
3 Months · Tout sèks · Mizajou Nov 12, 2025 · NCT02143830Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.